DNA methylation, genomic silencing, and links to nutrition and cancer

Nutrition Reviews

Volumn 63, Issue 6 I, 2005, Pages 183-195

  McCabe, Dale C ^a   Caudill, Marie A ^a  

^a CALIFORNIA STATE POLYTECHNIC UNIVERSITY   (United States)

Author keywords

Cancer; DNA methylation; Folate; Gene expression

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); DNA; DNA METHYLTRANSFERASE; FOLIC ACID; METHIONINE; S ADENOSYLMETHIONINE;

AMINO ACID SEQUENCE; CANCER; CHROMATIN STRUCTURE; CHROMOSOME TRANSLOCATION; CPG ISLAND; DNA METHYLATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; EPIGENETICS; GENE EXPRESSION; GENE FUNCTION; GENE SILENCING; GENETIC LINKAGE; GENETIC STABILITY; GENETIC TRANSCRIPTION; GENOME IMPRINTING; HOST RESISTANCE; HUMAN; MICROSATELLITE INSTABILITY; NONHUMAN; NUTRIENT; NUTRITION; PROTEIN FAMILY; REVIEW; X CHROMOSOME INACTIVATION;

CHROMATIN; CHROMOSOMES, HUMAN, X; DNA METHYLATION; EPIGENESIS, GENETIC; GENE SILENCING; GENOME; GENOMIC INSTABILITY; HUMANS; NEOPLASMS; NUTRITION PHYSIOLOGY;

EID: 18344366366     PISSN: 00296643     EISSN: None     Source Type: Journal    
DOI: 10.1301/nr.2005.Jun.183-195     Document Type: Review

References (159)

1. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042-2054.
2. Geisler JP, Manahan KJ, Geisler HE. Evaluation of DNA methylation in the human genome: why examine it and what method to use. Eur J Gynaecol Oncol. 2004;25:19-24.
3. Popiela A, Keith G, Borzecki A, Popiela G, Manowiec M, Gabrys M. The meaning of the methylation of genomic DNA in the regulation of gene expression. Eur J Gynaecol Oncol. 2004;25:145-149.
4. Colot V, Rossignol JL. Eukaryotic DNA methylation as an evolutionary device. Bioessays. 1999;21:402-411.
5. Robertson KD, Wolffe AP. DNA methylation in health and disease. Nat Rev Genet. 2000;1:11-19.
6. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921.
7. Kelly TL, Trasler JM. Reproductive epigenetics. Clin Genet. 2004;65:247-260.
8. Costello JF, Plass C. Methylation matters. J Med Genet. 2001;38:285-303.
9. Cooper DN, Krawczak M. The mutational spectrum of single base-pair substitutions causing human genetic disease: patterns and predictions. Hum Genet. 1990;85:55-74.
10. Gaudet F, Rideout WM 3rd, Meissner A, Dausman J, Leonhardt H, Jaenisch R. Dnmt1 expression in pre- and postimplantation embryogenesis and the maintenance of IAP silencing. Mol Cell Biol. 2004; 24:1640-1648.
11. Poirier LA. The effects of diet, genetics and chemicals on toxicity and aberrant DNA methylation: an introduction. J Nutr. 2002;132(suppl 8):2336S-2339S.
12. Cantoni GL. The role of S-adenosylhomocysteine in the biological utilization of S-adenosylmethionine. Prog Clin Biol Res. 1985;198:47-65.
13. Robertson KD. DNA methylation and chromatin: unraveling the tangled web. Oncogene. 2002;21: 5361-5379.
14. Bacolla A, Pradhan S, Roberts RJ, Wells RD. Recombinant human DNA (cytosine-5) methyltransferase. II. Steady-state kinetics reveal allosteric activation by methylated DNA. J Biol Chem. 1999; 274:33011-33019.
15. Glickman JF, Flynn J, Reich NO. Purification and characterization of recombinant baculovirus-expressed mouse DNA methyltransferase. Biochem Biophys Res Commun. 1997;230:280-284.
16. Leonhardt H, Page AW, Weier H-U, Bestor TH. A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. Cell. 1992;71:865-873.
17. Liu Y, Oakeley EJ, Sun L, Jost JP. Multiple domains are involved in the targeting of the mouse DNA methyltransferase to the DNA replication foci. Nucleic Acids Res. 1998;26:1038-1045.
18. Chen T, Ueda Y, Dodge JE, Wang Z, Li E. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol Cell Biol. 2003;23: 5594-5605.
19. Bachman KE, Rountree MR, Baylin SB. Dmnt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J Biol Chem. 2001;276:32282-32287.
20. Clarke S, Banfield K. S-adenosylmethionine-dependent methyltransferases. In: Carmel R, Jacobsen DW, eds. Homocysteine in Health and Disease. Cambridge, MA: Cambridge University Press; 200163-200178.
21. Bird AP. Gene number, noise reduction and biological complexity. Trends Genet. 1995;11:94-100.
22. Yoder JA, Walsh CP, Bestor TH. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 1997;13:335-340.
23. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003; 33(suppl);245-254.
24. Fazzari MJ, Greally JM. Epigenomics: beyond CpG islands. Nat Rev Genet. 2004;5:446-455.
25. von Sternberg RV. On the roles of repetitive DNA elements in the context of a unified genomic-epigenetic system. Ann N Y Acad Sci. 2002;981:154-188.
26. Lyon MF. X-chromosome inactivation: a repeat hypothesis. Cytogenet Cell Genet. 1998;80:133-137.
27. Wutz A, Jaenisch R. A shift from reversible to irreversible X inactivation is triggered during ES cell differentiation. Mol Cell. 2000;5:695-705.
28. Avner P, Heard E. X-chromosome inactivation: counting, choice and initiation. Nat Rev Genet. 2001;2:59-67.
29. Heard E. Recent advances in X-chromosome inactivation. Curr Opin Cell Biol. 2004;16:247-255.
30. Lee JT. Molecular links between X-inactivation and autosomal imprinting: X-inactivation as a driving force for the evolution of imprinting? Curr Biol. 2003;13:R242-R254.
31. Ke X, Collins A. CpG islands in human X-inactivation. Ann Human Genet. 2003;67(part 3):242-249.
32. Allaman-Pillet N, Djemai A, Bonny C, Schorderet D F. Methylation status of CpG sites and methylation CpG binding proteins are involved in the promoter regulation of the mouse Xist gene. Gene Expr. 1998;7:61-73.
33. Cross SH, Bird AP. CpG islands and genes. Curr Opin Genet Dev. 1995;5:309-314.
34. Lee JT, Davidow LS, Warshawsky D. Tsix, a gene antisense to Xist at the X-inactivation centre. Nat Genet. 1999;21:400-404.
35. Chao W, Huynh KD, Spencer RJ, Davidow LS, Lee JT. CTCF, a candidate trans-acting factor for X-inactivation choice. Science. 2002;295:345-347.
36. Jaenisch R. DNA methylation and imprinting: Why bother? Trends Genet. 1997;13:323-329.
37. Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. Nature. 1993;366: 362-365.
38. Chedin F, Lieber MR, Hsieh CL. The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by Dnmt3a. Proc Natl Acad Sci U S A. 2002;99:16916-16921.
39. Bourc'his D, Xu GL, Lin CS, Bollman B, Bestor TH. Dnmt3L and the establishment of maternal genomic imprints. Science. 2001;294:2536-2539.
40. Grady WM. Genomic instability and colon cancer. Can Metastasis Rev. 2004;23:11-27.
41. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396: 643-649.
42. Eshleman JR, Markowitz SD. Microsatellite instability in inherited and sporadic neoplasms. Curr Opin Oncol. 1995;7:83-89.
43. Veigl ML, Kasturi L, Olechnowicz J, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA. 1993;95:8698-8702.
44. Deng G, Chen A, Pong E, Kim YS. Methylation in MLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression. Oncogene. 2001;20:7120-7127.
45. Grady WM, Willis J, Guilford PJ, et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet. 2000; 26:16-17
46. Etoh T, Kanai Y, Ushijima S, et al. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol. 2004;164:689-699.
47. Gaudet F, Hodgson JG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation. Science. 2003;300:489-492.
48. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003;300:455.
49. Maloisel L, Rossignol JL. Suppression of crossing-over by DNA methylation in Ascobolus. Genes Dev. 1998;12:1381-1389.
50. Xu GL, Bestor TH, Bourc'his D, et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature. 1999;402:187-191.
51. Kondo T, Bobek MP, Kuick R, et al. Whole-genome methylation scan in ICF syndrome: hypomethylation of non-satellite DNA repeats D4Z4 and NBL2. Hum Mol Genet. 2000;9:597-604.
52. Ehrlich M. DNA hypomethylation, cancer, the immunodeficiency, centromeric region instability, facial anomalies syndrome and chromosomal rearrangements. J Nutr. 2002;132(suppl 8):2424S-2429S.
53. Sawyer JR, Tricot G, Mattox S, Jagannath S, Barlogie B. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood. 1998;91:1732-1741.
54. Geiman TM, Robertson KD. Chromatin remodeling, histone modifications, and DNA methylation-how does it all fit together? J Cell Biochem. 2002; 87:117-125.
55. Craig JM. Heterochromatin: many flavours, common themes. BioEssays. 2005;27:17-28.
56. Lachner M, Jenuwein T. The many faces of histone lysine methylation. Curr Opin Cell Biol. 2002;14: 286-298.
57. Tamaru H, Selker EU. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature. 2001;414:277-283.
58. Jackson JP, Lindroth AM, Cao X, Jacobsen SE. Control of CpNpG DNA methylation by the kryptonite histone H3 methyltransferase. Nature. 2002; 416:556-560.
59. Gendrel AV, Lippman Z, Yordan C, Colot V, Martienssen RA. Dependence of heterochromatic histone H3 methylation patterns on the Arabidopsis gene DDM1. Science. 2002;297:1871-1873.
60. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293:1074-1080.
61. Wang Y, Fischle W, Wang C, Jacobs S, Khorasanizadeh S, Allis CD. Beyond the double helix: writing and reading the histone code. Novartis Found Symp. 2004;259:3-21.
62. Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell. 2003;3:89-95.
63. Grewal SIS, Rice JC. Regulation of heterochromatin by histone methylation and small RNAs. Curr Opin Cell Biol. 2004;16:230-238.
64. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5:522-531.
65. Kawasaki H, Taira K. Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature. 2004;431:211-217.
66. Morris KV, Chan SW, Jacobsen SE, Looney DJ. Small interfering RNA-induced transcriptional gene silencing in human cells. Science. 2004;305:1289-1292.
67. Yi P, Melnyk S, Pogribna M, Pogribny IP, Hine RJ, James SJ. Increases in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem. 2000;275:29318-29323.
68. Shivapurkar N, Poirier LA. Tissue levels of S-adenosylmethionine and S-adenosylhomocysteine in rats fed methyl-deficient, amino acid-defined diets for one to five weeks. Carcinogenesis. 1983;4: 1051-1057.
69. Wainfan E, Poirier LA. Methyl groups in carcinogenesis: effects on DNA methylation and gene expression. Cancer Res. 1992;52(suppl 7):2071s-2077s.
70. Pogribny IP, Basnakian AG, Miller BJ, Lopatina NG, Poirier LA, James SJ. Breaks in genomic DNA and within the p53 gene are associated with hypomethylation in livers of folate/methyl-deficient rats. Cancer Res. 1995;55:1894-1901.
71. Pogribny IP, James SJ, Jernigan S, Pogribna M. Genomic hypomethylation is specific for preneoplastic liver in folate/methyl deficient rats and does not occur in non-target tissues. Mutat Res. 2004; 548:53-59.
72. Lopatina NG, Vanyushin BV, Cronin GM, Poirer LA. Elevated expression and altered pattern of activity of DNA methyltransferase in liver tumors of rats fed methyl-deficient diets. Carcinogenesis. 1998;19: 1777-1781.
73. Balaghi M, Wagner C. DNA methylation in folate deficiency: use of CpG methylase. Biochem Biophys Res Commun. 1993;193:1184-1190.
74. Alonso-Aperte E, Varela-Moreiras G. Brain folate and DNA methylation in rats fed a choline deficient diet or treated with low doses of methotrexate. Int J Vitam Nutr Res. 1996;66:232-236.
75. Duthie SJ, Narayanan S, Brand GM, Grant G. DNA stability and genomic methylation status in colonocytes isolated from methyl-donor-deficient rats. Eur J Nutr. 2000;39:106-111.
76. Sohn KJ, Stempak JM, Reid S, Shirwadkar S, Mason JB, Kim YI. The effect of dietary folate on genomic and p53-specific DNA methylation in rat colon. Carcinogenesis. 2003;24:81-90.
77. Trasler J, Deng L, Melnuk S, et al. Impact of Dnmt1 deficiency, with and without low folate diets, on tumor numbers and DNA methylation in Min mice. Carcinogenesis. 2003;24:39-45.
78. Kim YI, Pogribny IP, Basnakian AG, et al. Folate deficiency in rats induces DNA strand breaks and hypomethylation within the p53 tumor suppressor gene. Am J Clin Nutr. 1997;65:46-52.
79. Choi SW, Friso S, Ghandour G, Bagley PJ, Selhub J, Mason JB. Vitamin B-12 deficiency induces anomalies of base substitution and methylation in the DNA of rat colonic epithelium. J Nutr. 2004; 134:750-755.
80. Rogers AE. Methyl donors in the diet and responses to chemical carcinogens. Am J Clin Nutr. 1995;61(suppl 3):659S-665S.
81. Niculescu MD, Zeisel SH. Diet, methyl donors and DNA methylation: Interactions between dietary folate, methionine and choline. J Nutr. 2002; 132(suppl 8):2333S-2335S.
82. James SJ, Pogribny IP, Pogribna M, Miller BJ, Jernigan S, Melnyk S. Mechanisms of DNA damage, DNA hypomethylation, and tumor progression in the folate/methyl-deficient rat model of hepatocarcinogenesis. J Nutr. 2003;133(11 suppl 1): 3740S-3747S.
83. Jacob RA, Gretz DM, Taylor PC, et al. Moderate folate depletion increases plasma homocysteine and decreases lymphocyte DNA methylation in post-menopausal women. J Nutr. 1998;128:1204-1212.
84. Rampersaud GC, Kauwell GP, Hutson AD, Cerda JJ, Bailey LB. Genomic DNA methylation decreases in response to moderate folate depletion in elderly women. Am J Clin Nutr. 2000;72:998-1003.
85. Pufulete M, Al-Ghnaniem R, Leather AJ, et al. Folate status, genomic DNA hypomethylation, a risk of colorectal adenoma and cancer: a case control study. Gastroenterology. 2003;124:1240-1248.
86. Fowler BM, Giuliano AR, Piyathilake C, Nour M, Hatch K. Hypomethylation in cervical tissue: is there a correlation with folate status? Cancer Epidemiol Biomarkers Prev. 1998;7:901-906.
87. Fang JY, Xiao SD, Zhu SS, Yuan JM, Qiu DK, Jiang SJ. Relationship of plasma folic acid and status of DNA methylation in human gastric cancer. J Gastroenterol. 1997;32:171-175.
88. Friso S, Choi SW, Girelli D, et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci U S A. 2002;99:5606-5611.
89. Cravo M, Fidalgo P, Pereira AD, et al. DNA methylation as an intermediate in colorectal cancer: modulation by folic acid supplementation. Eur J Cancer Prev. 1994;3:473-479.
90. Kim YI, Baik HW, Fawaz K, et al. Effects of folate supplementation on two provisional molecular makers of colon cancer: a prospective, randomized trial. Am J Gastroenterol. 2001;96:184-195.
91. Ingrosso D, Cimmino A, Perna AF, et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet. 2003;361:1693-1699.
92. Duthie SJ, Narayanan S, Blum S, Pirie L, Brand GM. Folate deficiency in vitro induces uracil misincorporation and DNA hypomethylation and inhibits DNA excision repair in immortalized normal human colon epithelial cells. Nutr Cancer. 2000;37: 245-251.
93. Fenech M, Aitken C, Rinaldi J. Folate, vitamin B12, homocysteine status and DNA damage in young Australian adults. Carcinogenesis. 1998;19:1163-1171.
94. Cravo M, Gloria L, Salazar De Sousa L, et al. Folate status, DNA methylation and colon cancer risk in inflammatory bowel disease. Clin Nutr. 1995;14: 50-53.
95. Cravo ML, Pinto AG, Chaves P, et al. Effect of folate supplementation on DNA methylation of rectal mucosa in patients with colonic adenomas: correlation with nutrient intake. Clin Nutr. 1998;17: 45-49.
96. Kim YI. Folate and DNA methylation: A mechanistic link between folate deficiency and colorectal cancer? Cancer Epidimiol Biomarkers Prev. 2004; 13:511-519.
97. Guinotte CL, Burns MG, Axume JA, et al. Methylenetetrahydrofolate reductase 677C→T variant modulates folate status response to controlled folate intakes in young women. J Nutr. 2003;133: 1272-1280.
98. Weisberg IS, Jacques PF, Selhub J, et al. The 1298 A→C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis. 2001; 156:409-415.
99. Harmon DL, Shields DC, Woodside JV, et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol. 1999;17:298-309.
100. Tsai MY, Bignell M, Yang F, Welge BG, Graham KJ, Hanson NQ. Polygenic influence on plasma homocysteine: association of two prevalent mutations, the 844ins68 of cystathionine beta-synthase and A2756G of methionine synthase, with lowered plasma homocysteine levels. Atherosclerosis. 2000;149:131-137.
101. Yates Z, Lucock M. Interaction between common folate polymorphisms and B-vitamin nutritional status modulates homocysteine and risk for a thrombotic event. Mol Genet Metab. 2003;79:201-213.
102. Sharp L, Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: A HuGE review. Am J Epidemiol. 2004;159:423-443.
103. Goode EL, Potter JD, Bigler J, Ulrich CM. Methionine synthase D919G polymorphism, folate metabolism, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev. 2004;13:157-162.
104. Stolzenberg-Solomon R, Qiao YL, Abnet CC, et al. Esophageal and gastric cardia cancer risk and folate-and vitamin B12-related polymorphisms in Linxian, China. Cancer Epidemiol Biomarkers Prev. 2003;12(11 part 1):1222-1226.
105. Shannon B, Gnanasampanthan S, Beilby J, Iacopetta B. A polymorphism in the methylenetetrahydrofolate reductase gene predisposes to colorectal cancers with microsatellite instability. Gut. 2002;50:520-524.
106. Tseng TL, Shih YP, Huang YC, et al. Genotypic and phenotypic characterization of a putative tumor susceptibility gene, GNMT, in liver cancer. Cancer Res. 2003;63:647-654.
107. Cho M, Uemura H, Kim SC, et al. Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma. Br J Cancer. 2001;85:563-567.
108. Esteller M, Corn PG, Urena JM, et al. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res. 1998;58:4515-4518.
109. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225-3229.
110. Morrissey C, Martinez A, Zatyka M, et al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res. 2001;61:7277-7281.
111. Cairns P. Detection of promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Ann N Y Acad Sci. 2004;1022:40-43.
112. Hoque MO, Begum S, Topaloglu O, et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res. 2004; 64:5511-5517.
113. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene. 2002;21:5400-5413.
114. Chalitchagorn K, Shuangshoti S, Hourpai N, et al. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene. 2004;23:8841-8846.
115. Jackson K, Yu MC, Arakawa K, et al. DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther. 2004;3:1225-1231.
116. Widschwendter M, Jiang G, Woods C, et al. DNA hypomethylation and ovarian cancer biology. Cancer Res. 2004;64:4472-4480.
117. Agathanggelou A, Honorio S, Macartney DP, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene. 2001;20:1509-1518.
118. Yang X, Yan L, Davidson NE. DNA methylation in breast cancer. Endocr Relat Cancer. 2001;8:115-127.
119. Kobatake T, Yano M, Toyooka S, et al. Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. Oncol Rep. 2004;12:1087-1092.
120. Kim YI, Giuliano A, Hatch KD, et al. Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma. Cancer. 1994;74: 893-899.
121. Yang HJ, Liu VW, Wang Y, et al. Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. Gynecol Oncol. 2004;93: 435-440.
122. Dante R, Dante-Paire J, Rigal D, Roizes G. Methylation patterns of long interspersed repeated DNA and alphoid repetitive DNA from human cell lines and tumors. Anticancer Res. 1992;12:559-563.
123. Suter CM, Martin DI, Ward RL. Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue. Int J Colorectal Dis. 2004;19: 95-101.
124. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nature Genet. 1994;7:536-540.
125. Arnold CN, Goel A, Compton C, et al. Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biol Ther. 2004;3:73-78.
126. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000;24:132-138.
127. Ku JL, Kang SB, Shin YK, et al. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene. 2004;23:6736-6742.
128. Santourlidis S, Florl A, Ackermann R, Wirtz HC, Schulz WA. High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate. 1999;39:166-174.
129. Schulz WA, Elo JP, Florl AR, et al. Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer. 2002;35:58-65.
130. Lee W-H, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the π-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A. 1994;91:11733-11737.
131. Li LC, Chui R, Nakajima K, Oh BR, Au HC, Dahiya R. Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res. 2000;60:702-706.
132. Bernardini S, Miano R, Iori R, et al. Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker? Clin Chim Acta. 2004;350:181-188.
133. Takai D, Yagi Y, Habib N, Sugimura T, Ushijima T. Hypomethylation of LINE1 retrotransposon in human hepatocellular carcinomas, but not in surrounding liver cirrhosis. Jpn J Clin Oncol. 2000;30: 306-309.
134. Yu J, Ni M, Xu J, et al. Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer. 2002;2:29.
135. Uhlmann K, Rohde K, Zeller C. Distinct methylation profiles of glioma subtypes. Int J Cancer. 2003; 106:52-59.
136. Gonzalez-Gomez P, Bello MJ, Alonso ME, et al. CpG island methylation status and mutation analysis of the RBI gene essential promoter region and protein-binding pocket domain in nervous system tumours. Br J Cancer. 2003;88:109-114.
137. Sanchez-Cespedes M, Esteller M, Wu L, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 2000;60:892-895.
138. Peltomaki P. DNA methylation changes in human testicular cancer. Biochim Biophys Acta. 1991; 1096:187-196.
139. Smith-Sorensen B, Lind GE, Skotheim RI, et al. Frequent promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene in testicular cancer. Oncogene. 2002;21:8878-8884.
140. Jurgens B, Schmitz-Drager BJ, Schulz WA. Hypomethylation of L1 LINE sequences prevailing in human urothelial carcinoma. Cancer Res. 1996;56: 5698-5703.
141. Gutierrez MI, Siraj AK, Khaled H, Koon N, El-Rifai W, Bhatia K. CpG island methylation in Schistosoma and non-Schistosoma-associated bladder cancer. Mod Pathol. 2004;17:1268-1274.
142. Kawakami K, Brabender J, Lord RV, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst. 2000;92:1805-1811.
143. Harden SV, Tokumaru Y, Westra WH, et al. Gene promoter hypermethylation in tumors and lymph nodes of stage 1 lung cancer patients. Clin Cancer Res. 2003;9:1370-1375.
144. Dunn JR, Panutsopulos D, Shaw MW, et al. METH-2 silencing and promoter hypermethylation in NSCLC. Br J Cancer. 2004;91:1149-1154.
145. Rosty C, Ueki T, Argani P, et al. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol. 2002;160:45-50.
146. Sato N, Maitra A, Fukushima N, et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res. 2003;63:4158-4166.
147. Sakai M, Hibi K, Koshikawa K, et al. Frequent promoter methylation and gene silencing of CDH13 in pancreatic cancer. Cancer Sci. 2004;95: 588-591.
148. de Capoa A, Musolino A, Della Rosa S, et al. DNA demethylation is directly related to tumour progression: evidence in normal, pre-malignant and malignant cells from uterine cervix samples. Oncol Rep. 2003;10:545-549.
149. Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene. 1999;18:2335-2341.
150. Ibanez de Caceres I, Battagli C, Esteller M, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 2004; 64:6476-6481.
151. Nakayama M, Wada M, Harada T, et al. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood. 1998;92: 4296-4307.
152. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;65: 141-196.
153. Kaneda A, Tsukamoto T, Takamura-Enya T, et al. Frequent hypomethylation in multiple promoter CpG islands is associated with frequent promoter hypermethylation. Cancer Sci. 2004;95:58-64.
154. Smith SS, Kan JL, Baker DJ, Kaplan BE, Dembek P. Recognition of unusual DNA structures by human DNA (cytosine-5) methyltransferase. J Mol Biol. 1991;217:39-51.
155. Kho MR, Baker DJ, Laayoun A, Smith SS. Stalling of human DNA (cytosine-5) methyltransferase at single-strand conformers from a site of dynamic mutation. J Mol Biol. 1998;275:67-79.
156. Liang G, Chan MF, Tomigahara Y, et al. Cooper-ativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol. 2002;22:480-491.
157. Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002;416:552-556.
158. Robertson KD, Uzvolgyi E, Liang G, et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 1999;27:2291-2298.
159. Saito Y, Kanai T, Sakamoto M, Saito H, Ishii H, Hirohashi S. Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, associated with DNA hypomethylation on pericentromeric satellite regions during human hepatocarcinogenesis. Proc Natl Acad Sci U S A. 2002;99: 10060-10065.